Tag: $Abbott Laboratories

Abbott Laboratories had higher revenue in the second quarter, boosted by more sales in its diagnostics business.

Abbott Laboratories reported first-quarter earnings in line with expectations and revenue above forecasts on Wednesday, but shares slipped after the medical device maker issued soft second-quarter profit guidance.

Shares of Abbott Laboratories (ABT) tumbled Thursday after the medical devices maker posted fourth-quarter earnings and sales that underwhelmed Wall Street.

Abbott missed analysts’ estimates for third-quarter revenue on Wednesday, as weakness in its diagnostics and nutritional businesses failed to offset strong demand for its medical devices, sending its shares down 3% premarket.

Abbott (ABT.N), beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its medical devices including continuous glucose monitors.

Abbott Laboratories ABT-0.90% declined slightly in premarket trading Wednesday after the healthcare company posted first-quarter sales that missed Wall Street expectations.

Abbott Laboratories shares rose nearly 5% before the bell on Friday, after a jury cleared the company and a Reckitt unit of liability in a lawsuit over their premature baby formulas’ risks.

The maker of healthcare products posted adjusted earnings of $1.21 per share for the third quarter, topping Wall Street’s call for $1.20, according to FactSet.

Abbott Laboratories shares were falling ahead of the opening bell on Monday after a jury found the company had failed to warn that its premature baby formula could increase infants’ risk of developing a potentially deadly bowel illness.